SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Gilead Signs Voluntary Licensing Deals for Investigational Ebola Drug

Gilead Sciences said it signed voluntary licensing deals to expand access to its investigational Ebola drug.

GILD

Story updates

10:05:48 PM UTC
SquawkNews
Gilead Sciences NASDAQ:GILD said on Monday it had signed royalty-free deals with three generic drugmakers to make its experimental Ebola prevention drug available in 127 mainly low- and lower-middle-income countries if it succeeds in trials and wins regulatory approvals.Here are more details

Related stories